- Home
- MYO vs NRXS Comparison
MYO vs NRXS Comparison
Compare MYO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYO | NRXS |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 44.7M |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MYO | NRXS |
|---|---|---|
| Price | $1.06 | $4.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $8.00 |
| AVG Volume (30 Days) | 767.8K | ★ 910.1K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,643,203.00 | $3,362,320.00 |
| Revenue This Year | $24.07 | $31.05 |
| Revenue Next Year | $17.48 | $137.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 65.00 | 36.89 |
| 52 Week Low | $0.71 | $1.33 |
| 52 Week High | $7.17 | $6.20 |
Technical Indicators
Market Signals| Indicator | MYO | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 72.84 |
| Support Level | $0.96 | $2.63 |
| Resistance Level | $1.05 | $4.64 |
| Average True Range (ATR) | 0.08 | 0.41 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 75.05 | 88.54 |
Price Performance
Historical ComparisonAbout MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).